AZELEX Drug Patent Profile

When do Azelex patents expire, and when can generic versions of Azelex launch?

Azelex is a drug marketed by Almirall and is included in one NDA.

The generic ingredient in AZELEX is azelaic acid. There are eight drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the azelaic acid profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Azelex

A generic version of AZELEX was approved as azelaic acid by ACTAVIS LABS UT INC on November 19^th, 2018.

Summary for AZELEX

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	116
Patent Applications:	3,397
Drug Prices:	Drug price information for AZELEX
What excipients (inactive ingredients) are in AZELEX?	AZELEX excipients list
DailyMed Link:	AZELEX at DailyMed

See drug prices for AZELEX

Pharmacology for AZELEX

Physiological Effect

Decreased Protein Synthesis Decreased Sebaceous Gland Activity

US Patents and Regulatory Information for AZELEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Almirall	AZELEX	azelaic acid	CREAM;TOPICAL	020428-001	Sep 13, 1995		RX	Yes	Yes

Expired US Patents for AZELEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Almirall	AZELEX	azelaic acid	CREAM;TOPICAL	020428-001	Sep 13, 1995

International Patents for AZELEX

See the table below for patents covering AZELEX around the world.

Country	Patent Number	Title	Estimated Expiration
United Kingdom	1603563
Australia	3502778
South Africa	7802125
Italy	1075741	COMPOSIZIONE PER IL TRATTAMENTO DI DERMATOSI IPERPIGMENTARIE
Italy	1114950	COMPOSIZIONI PER IL TRATTAMENTO E LA TERAPIA DI ACNE

Market Dynamics and Financial Trajectory for AZELEX (Azelastine Hydrochloride)

Last updated: March 19, 2026

What is AZELEX and its current market positioning?

AZELEX is a nasal spray formulation of azelastine hydrochloride, marketed primarily for allergic rhinitis and chronic rhinitis. It belongs to the antihistamine class, targeting H1 receptors. AZELEX faces competition from multiple intranasal antihistamines, notably Flonase (fluticasone) and Nasacort (triamcinolone).

AZELEX's primary markets are North America, Europe, and select Asia-Pacific countries. It is available via prescription in most jurisdictions. The drug's revenue generation depends on its market penetration, reimbursement policies, and competitive landscape.

What are the key market drivers for AZELEX?

• Increasing prevalence of allergic rhinitis: The condition affects approximately 20-30% of the global population, with rising incidence in urban settings.
• Growing awareness of nasal spray treatments: Patients and physicians increasingly prefer nasal sprays over oral medications due to targeted delivery and fewer systemic side effects.
• Expanding healthcare access: Especially in emerging markets, facilitates product availability.
• Product innovations: Potential formulations with improved bioavailability or reduced side effects could enhance market share.

What are the primary market challenges?

• Intense competition: Multiple established antihistamines dominate the scene, making AZELEX’s market share highly contested.
• Generic entrants: Many azelastine formulations are available as generics, exerting downward pressure on prices.
• Regulatory hurdles: Approval processes vary, particularly concerning new indications or formulations.
• Limited awareness or prescriber preference: Physicians may prefer corticosteroid nasal sprays over antihistamines for certain patient segments.

How has AZELEX's sales trended historically?

While specific sales figures are proprietary or variably reported, industry estimates suggest initial global sales of AZELEX ranged from $50 million to $150 million annually as of 2022. Sales growth has been modest, influenced by patent expirations, generic competition, and stagnant market penetration in some regions.

In the U.S., AZELEX holds a limited market share relative to dominant brands like Flonase, which reported global revenues exceeding $900 million in 2021. The influence of patent life—expiring in 2024—significantly affects revenue trajectories.

What is the role of patent exclusivity in AZELEX's financial outlook?

AZELEX's patent protections have historically extended until 2024 in the U.S. and similar periods elsewhere. Expiration opens the door for generics, which can rapidly erode sales.

Estimates suggest that upon patent expiry, AZELEX sales may decline by 70-80%, aligning with patterns seen in other branded antihistamines after patent cliffs. Companies often attempt to offset revenue loss via:

• Line extensions (such as combination therapies)
• New formulations
• Expanded indications

What are the financial projections for AZELEX?

Projected revenue decline post-2024 suggests:

Year	Estimated Revenue	Comments
2023	$50-150 million	Peak sales before patent expiry
2024	$5-15 million	Sharp decline expected due to generic entry
2025+	<$10 million	Revenue driven primarily by remaining markets or niche uses

Long-term prospects depend on the profitability of generic products and the company's ability to innovate or expand indications.

How do regulatory and policy factors influence AZELEX's trajectory?

• Regulatory approvals: Delays in approval of new formulations can hinder growth.
• Reimbursement policies: Health insurer willingness to cover branded drugs impacts sales.
• Pricing regulations: Stringent pricing controls in certain markets can limit revenue growth.

Can AZELEX capitalize on market opportunities?

Market expansion relies on:

• Launching in emerging markets with high allergic rhinitis prevalence
• Developing new formulations with improved efficacy or convenience
• Securing new indications, such as ocular allergies, if data permits

Summary

AZELEX's market is characterized by high competition, patent dependency, and moderate growth potential. Revenue is expected to decline sharply after patent expiry unless offset by product innovations, market expansion, or strategic repositioning.

Key Takeaways

• AZELEX faces significant revenue erosion post-2024 due to patent expiration.
• Competition from generics and inhaled corticosteroids limits market share.
• Prospects hinge on pipeline innovations, regional expansion, and regulatory strategies.
• Historically, sales have been modest relative to leading antihistamines, with recent trends indicating stagnation.
• Strategic actions prior to patent expiry are critical to maximize value.

FAQs

1. When does AZELEX’s patent protection expire?
The primary patent in the U.S. expires in 2024, with supplementary patents and exclusivities varying by jurisdiction.

2. Which competitors are most relevant to AZELEX?
Fluticasone (Flonase), triamcinolone (Nasacort), and other antihistamine nasal sprays dominate sales in the allergy treatment segment.

3. Can AZELEX's sales be sustained through new indications?
Potentially, but approval processes and clinical trial requirements can delay or hinder such expansion.

4. What strategies can extend AZELEX’s market life?
Investing in formulation innovations, geographic expansion, or combination therapies offer pathways to prolong profitability.

5. How does the generic market impact AZELEX?
The entrance of generics typically reduces price points and market share, sharply impacting revenue.

---

References

[1] IMS Health, 2022. Global sales data on antihistamines.
[2] U.S. Food and Drug Administration (FDA), 2023. AZELEX patent and approval details.
[3] Market Research Future, 2022. Allergy Treatment Market Overview.